391 related articles for article (PubMed ID: 31724803)
1. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
2. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
[TBL] [Abstract][Full Text] [Related]
3. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
6. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
7. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
[TBL] [Abstract][Full Text] [Related]
8. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
12. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Nachmias B; Shaulov A; Gatt ME; Shapira M; Gural A
Acta Haematol; 2018; 140(4):209-214. PubMed ID: 30343286
[TBL] [Abstract][Full Text] [Related]
13. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
16. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.
Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Hallböök H
Haematologica; 2012 Sep; 97(9):1414-21. PubMed ID: 22511497
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
Nickel RS; Keller F; Bergsagel J; Cooper T; Daves M; Sabnis H; Lew G
Pediatr Blood Cancer; 2014 May; 61(5):810-4. PubMed ID: 24357218
[TBL] [Abstract][Full Text] [Related]
18. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
[TBL] [Abstract][Full Text] [Related]
19. FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
Ravichandran N; Uppuluri R; Swaminathan VV; Patel S; Ramanan KM; Jayakumar I; Ramakrishnan B; Raj R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e212-e214. PubMed ID: 31688621
[TBL] [Abstract][Full Text] [Related]
20. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]